Brief: Novo To Share Real-World, Clinical Data At EASD 2026
16/09/2026 08:01
BRIEF-Novo To Share Real-World, Clinical Data At EASD 2026 Sept 16 (Reuters) - Novo Nordisk A/S NOVOb.CO:
TO SHARE REAL-WORLD AND CLINICAL DATA INCLUDING WEGOVY® PILL, AND CARDIOMETABOLIC PIPELINE PROGRESS WITH NEXT-GENERATION AMYLIN TREATMENTS AT EASD 2026
TO PRESENT NEW CARDIOMETABOLIC DATA AT EASD 2026 IN MILAN SEPT 28-OCT 2
Source text: ID:nGNE7F9Z5p
Further company coverage: [NOVOb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals